人工智能在乳腺X线摄影中检测乳腺癌:与癌症检出相关的因素
该回顾性研究纳入2016年4月至2019年12月间接受乳腺癌手术的1001例无症状女性,使用商用AI软件(Lunit INSIGHT MMG Ver.1.1.4.0)对术前乳腺X线摄影分配异常评分(≥10为阳性)。AI正确检出717个(72%)癌症,未检出284个(28%);多变量分析显示异常乳腺X线表现、浸润性肿瘤大小和HER2阳性与更高异常评分相关。
要点
- AI对乳腺X线摄影的癌症检出率为72%(717/1001),未检出率为28%(284/1001)。
- 回顾性阅片有异常表现(肿块、钙化、结构扭曲、不对称)的癌症AI异常评分更高。
- AI未能检出致密乳腺中的小不对称、亚厘米或等密度病灶以及模糊无定形钙化。
核心结论
- 回顾性阅片有异常乳腺X线表现、浸润性肿瘤较大、HER2阳性的癌症具有较高的AI异常评分;理解AI软件的性能模式对于将其有效整合到临床实践至关重要。
研究设计与样本
- 回顾性数据库搜索,纳入2016年4月至2019年12月连续无症状接受乳腺癌手术的女性1001例(1001个指标癌症:830个浸润性癌和171个导管原位癌);使用商用AI软件(Lunit INSIGHT, MMG, Ver. 1.1.4.0)对术前乳腺X线摄影分配异常评分,评分≥10视为AI阳性检出;由不知晓AI结果的放射科医生回顾性评估乳腺密度并将乳腺X线表现分类为阳性和阴性;采用一般线性模型(GLM)分析确定与异常评分相关的临床、病理和乳腺X线表现因素。
关键影像表现/征象
- AI正确检出717个(72%)癌症,未检出284个(28%)。
- AI未能检出致密乳腺中的小不对称、亚厘米大小或等密度病灶以及模糊无定形钙化。
诊断标准与关键数值
- AI软件异常评分≥10视为阳性检出。
- 多变量GLM分析显示,与阴性表现相比,异常乳腺X线表现与更高平均异常评分相关:肿块β=77.0、仅钙化β=73.1、结构扭曲β=49.4、不对称β=47.6(所有P<0.001)。
- 浸润性肿瘤大小每增加1 cm,平均异常评分β=4.3(P<0.001)。
- HER2阳性与激素受体阳性/HER2阴性相比,平均异常评分β=9.2(P=0.004)。
临床应用与阅片要点
- AI对回顾性阅片有异常表现(肿块、钙化、结构扭曲、不对称)的癌症评分更高。
- AI对致密乳腺中的小不对称、亚厘米或等密度病灶及模糊无定形钙化可能未检出。
- 理解AI软件的性能模式对于将其有效整合到临床实践至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Little is known about the factors affecting the Artificial Intelligence (AI) software performance on mammography for breast cancer detection. This study was to identify factors associated with abnormality scores assigned by the AI software.
MATERIALS AND METHODS: A retrospective database search was conducted to identify consecutive asymptomatic women who underwent breast cancer surgery between April 2016 and December 2019. A commercially available AI software (Lunit INSIGHT, MMG, Ver. 1.1.4.0) was used for preoperative mammography to assign individual abnormality scores to the lesions and score of 10 or higher was considered as positive detection by AI software. Radiologists without knowledge of the AI results retrospectively assessed the mammographic density and classified mammographic findings into positive and negative finding. General linear model (GLM) analysis was used to identify the clinical, pathological, and mammographic findings related to the abnormality scores, obtaining coefficient β values that represent the mean difference per unit or comparison with the reference value. Additionally, the reasons for non-detection by the AI software were investigated.
RESULTS: Among the 1001 index cancers (830 invasive cancers and 171 ductal carcinoma in situs) in 1001 patients, 717 (72%) were correctly detected by AI, while the remaining 284 (28%) were not detected. Multivariable GLM analysis showed that abnormal mammography findings (β = 77.0 for mass, β = 73.1 for calcification only, β = 49.4 for architectural distortion, and β = 47.6 for asymmetry compared to negative; all Ps < 0.001), invasive tumor size (β = 4.3 per 1 cm, P < 0.001), and human epidermal growth receptor type 2 (HER2) positivity (β = 9.2 compared to hormone receptor positive, HER2 negative, P = 0.004) were associated with higher mean abnormality score. AI failed to detect small asymmetries in extremely dense breasts, subcentimeter-sized or isodense lesions, and faint amorphous calcifications.
CONCLUSION: Cancers with positive abnormal mammographic findings on retrospective review, large invasive size, HER2 positivity had high AI abnormality scores. Understanding the patterns of AI software performance is crucial for effectively integrating AI into clinical practice.
引用
- Yoen H, Jang MJ, Yi A, et al. Artificial Intelligence for Breast Cancer Detection on Mammography: Factors Related to Cancer Detection. Acad Radiol. 2024. PMID: 38216413. doi:10.1016/j.acra.2023.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。